Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study)

ABSTRACT We studied the penetration of raltegravir and HIV shedding in the genital tract among 14 HIV-1-infected women receiving a raltegravir-containing regimen who had <40 copies/ml blood plasma (BP) HIV RNA. None of the cervicovaginal fluid (CVF) samples showed detectable HIV RNA. Median raltegravir concentrations were 235 ng/ml in BP and 93 ng/ml in CVF, with a CVF/BP ratio of approximately 2.3. This good penetration of raltegravir may contribute to the control of viral replication in the female genital tract.

[1]  V. Calvez,et al.  Low Frequency of Intermittent HIV-1 Semen Excretion in Patients Treated with Darunavir-Ritonavir at 600/100 Milligrams Twice a Day plus Two Nucleoside Reverse Transcriptase Inhibitors or Monotherapy , 2010, Antimicrobial Agents and Chemotherapy.

[2]  C. Delaugerre,et al.  High Concentration of Raltegravir in Semen of HIV-Infected Men: Results from a Substudy of the EASIER-ANRS 138 Trial , 2009, Antimicrobial Agents and Chemotherapy.

[3]  B. Damle,et al.  Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women , 2009, Journal of acquired immune deficiency syndromes.

[4]  C. Pasquier,et al.  Determining Seminal Plasma Human Immunodeficiency Virus Type 1 Load in the Context of Efficient Highly Active Antiretroviral Therapy , 2009, Journal of Clinical Microbiology.

[5]  H. Teppler,et al.  Effects of omeprazole on plasma levels of raltegravir. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  F. Brun-Vézinet,et al.  HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. , 2008, The Journal of antimicrobial chemotherapy.

[7]  C. Rouzioux,et al.  Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine. , 2008, The Journal of antimicrobial chemotherapy.

[8]  J. Hogan,et al.  Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Wagner,et al.  Safety, Tolerability, and Pharmacokinetics of Raltegravir After Single and Multiple Doses in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.

[10]  B. Jung,et al.  Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. , 2007, Biomedical chromatography : BMC.

[11]  Myron S. Cohen,et al.  Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis , 2007, AIDS.

[12]  A. Molinari,et al.  HIV-1 integrase inhibitors are substrates for the multidrug transporter MDR1-P-glycoprotein , 2007, Retrovirology.

[13]  K. Anastos,et al.  HIV-1 drug resistance in variants from the female genital tract and plasma. , 2007, The Journal of infectious diseases.

[14]  C. Kovacs,et al.  Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.

[15]  A. Caliendo,et al.  Differences in HIV-1 pol Sequences From Female Genital Tract and Blood During Antiretroviral Therapy , 2003, Journal of acquired immune deficiency syndromes.

[16]  M. Kazatchkine,et al.  Selection of drug-resistant variants in the female genital tract of human immunodeficiency virus type 1-infected women receiving antiretroviral therapy. , 2000, The Journal of infectious diseases.

[17]  A. Caliendo,et al.  Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA , 2000, AIDS.